SCHEMBL6224252

SCHEMBL6224252

O=C(CCC(Nc1ncnc2cc(C(=O)N3CCCC3)c(Cl)cc12)c1nc2ccc(Cl)cc2[nH]1)NC1CC1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 1/20 0.36
GRIN2B Q13224 1/20 0.36
HRH4 Q9H3N8 5/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CCRL2 O00421 1/20 0.35
CNR1 P21554 6/20 0.35
CNR2 P34972 3/20 0.35
EGFR P00533 1/20 0.35
F10 P00742 1/20 0.34
TNKS O95271 1/20 0.34
PARP2 Q9UGN5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6224761 0.98 POLB (0.42) POLBLMNAL3MBTL1KMT2AGRIN2B
SCHEMBL3004953 0.94 KMT2A (0.36) POLBKMT2AHRH4HRH3CCRL2
SCHEMBL3002040 0.92 POLB (0.37) POLBLMNAL3MBTL1KMT2AHRH4
SCHEMBL2996174 0.91 CNR1 (0.34) POLBKMT2AHRH4HRH3CCRL2
SCHEMBL6223373 0.89 BACE1 (0.38) POLBLMNAL3MBTL1KMT2AGRIN2B
SCHEMBL4141004 0.88 CNR1 (0.34) KMT2ACNR1CNR2EGFR
SCHEMBL6226058 0.86 HRH4 (0.41) HRH4HRH3CNR1CNR2EGFR
SCHEMBL6226694 0.85 HRH4 (0.37) LMNAL3MBTL1GRIN2BHRH4HRH3
SCHEMBL3000705 0.85 EGFR (0.33) HRH4HRH3CCRL2CNR1CNR2
SCHEMBL2997119 0.84 ALDH1A1 (0.35) LMNAKMT2AHRH4HRH3CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583757-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-10-12 EP disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed